Sep 29, 2023

Optimizing CAR T cell therapy with bridging radiation therapy

Posted by in category: biotech/medical

For many patients diagnosed with certain types of B-cell lymphoma, leukemia and multiple myeloma, chimeric antigen receptor (CAR) T cell therapy offers an effective treatment option. This cellular therapy is created by extracting a patient’s T cells, modifying them in a lab to identify and attack cancer cells, and returning them to the patient.

The process of creating the CAR T cells can take three to four weeks. Radiation therapy can be a tool to help get a patient through this manufacturing period. This is called bridging therapy.

“Bridging therapy can help control the disease so that a patient can get to the CAR T cell infusion,” says radiation oncologist Penny Fang, M.D. Research from Fang and her colleagues examines the role of bridging therapy for B-cell lymphoma patients receiving CAR T cell therapy. Their latest findings will be presented at the 2023 American Society for Radiation Oncology Annual Meeting.

Leave a reply